Want to see IN:MARKSANS full AI Analyst Report?
MARKSANS Stock Chart & Stats
₹182.05
-₹6.40(-2.21%)
At close: 4:00 PM EST
₹182.05
-₹6.40(-2.21%)
Day’s Range― - ―
52-Week Range₹155.50 - ₹345.70
Previous CloseN/A
Volume681.00K
Average Volume (3M)99.03K
Market Cap
₹145.28B
Enterprise Value₹65.05K
Total Cash (Recent Filing)₹9.91B
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)28.2
Beta1.30
Next Earnings
Nov 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.28%
Share Statistics
EPS (TTM)11.41
Shares Outstanding453,163,760
10 Day Avg. Volume119,310
30 Day Avg. Volume99,030
Financial Highlights & Ratios
PEG Ratio1.74
Price to Book (P/B)2.35
Price to Sales (P/S)2.41
P/FCF Ratio20.26
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)12.45
Revenue Forecast (FY)₹35.69B
Bulls Say, Bears Say
Bulls Say
Revenue Growth And ProfitabilitySteady revenue expansion and durable mid-teen margins indicate continued demand for the company’s generic formulations and sound operating discipline, supporting earnings resilience across domestic and international markets.
Conservative Balance SheetLow leverage and a growing equity base reduce financial risk, preserve borrowing capacity, and give Marksans flexibility to fund manufacturing, product development, or expansion through changing industry conditions.
Improved Cash GenerationThe FY2026 rebound in operating and free cash flow suggests improved conversion of accounting profits into usable funds, strengthening the company’s ability to reinvest, reduce financial risk, and support operations internally.
Bears Say
Gross Margin CompressionA sharp decline in gross margin can signal adverse product mix, pricing pressure, or higher input costs. If persistent, it could constrain earnings growth even while revenue continues to expand.
Uneven Cash ConversionHistorically inconsistent conversion of profits into operating and free cash flow reduces confidence in earnings quality and may limit the consistency of internally funded investment, despite the strong FY2026 improvement.
Rising Debt ExposureWhile leverage remains low, rising debt introduces a gradual increase in fixed financial obligations. This could reduce flexibility if operating margins weaken or capital requirements rise across the manufacturing business.
Marksans Pharma Limited News
MARKSANS FAQ
What was Marksans Pharma Limited’s price range in the past 12 months?
Marksans Pharma Limited lowest stock price was ₹155.50 and its highest was ₹345.70 in the past 12 months.
What is Marksans Pharma Limited’s market cap?
Marksans Pharma Limited’s market cap is ₹145.28B.
When is Marksans Pharma Limited’s upcoming earnings report date?
Marksans Pharma Limited’s upcoming earnings report date is Nov 18, 2026 which is in 88 days.
How were Marksans Pharma Limited’s earnings last quarter?
Marksans Pharma Limited released its earnings results on Aug 12, 2026. The company reported ₹3.45 earnings per share for the quarter, beating the consensus estimate of ₹3.3 by ₹0.15.
Is Marksans Pharma Limited overvalued?
According to Wall Street analysts Marksans Pharma Limited’s price is currently Overvalued.
Does Marksans Pharma Limited pay dividends?
Marksans Pharma Limited pays a Annually dividend of ₹0.9 which represents an annual dividend yield of 0.28%. See more information on Marksans Pharma Limited dividends here
What is Marksans Pharma Limited’s EPS estimate?
Marksans Pharma Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Marksans Pharma Limited have?
Marksans Pharma Limited has 453,163,760 shares outstanding.
What happened to Marksans Pharma Limited’s price movement after its last earnings report?
Marksans Pharma Limited reported an EPS of ₹3.45 in its last earnings report, beating expectations of ₹3.3. Following the earnings report the stock price went up 12.137%.
Which hedge fund is a major shareholder of Marksans Pharma Limited?
Currently, no hedge funds are holding shares in IN:MARKSANS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Marksans Pharma Limited
Marksans Pharma Limited, along with its subsidiaries, operates internationally, engaging in the full spectrum of generic pharmaceutical formulation activities, from research and development and manufacturing to marketing, distribution, and sales. The company's extensive product portfolio addresses a wide array of medical needs across numerous therapeutic categories. These include pain management (analgesics), conditions such as benign prostatic hyperplasia and various forms of diabetes, neurological disorders like epilepsy, anti-inflammatory conditions, hyperparathyroidism, and gastrointestinal issues like those requiring antacids or treatments for gastroenterology. Marksans Pharma also develops solutions for cardiovascular health, hormonal imbalances, oncology, gynecology, and hypertension, alongside producing antibiotics, antifungals, antiulceratives, vitamins, dermatological preparations, cephalosporins, injectables, anti-allergy, and antibacterial medications. Furthermore, the firm offers contract research and manufacturing services. Established in 1992, its corporate headquarters are situated in Mumbai, India.
Technical Analysis
Cipla Ltd
―
Gland Pharma Ltd.
―
GlaxoSmithKline Pharmaceuticals Limited
―
PFIZER LIMITED
―
Sanofi India Limited
―